MedImmune expert speaker interview released in run up to Immuno-Oncology Conference
Exclusive interview with Grace Macaulay - MedImmune released in the run up to the Immuno-Oncology Conference, taking place on the 26 - 27 September 2018 in London.
List view / Grid view
Exclusive interview with Grace Macaulay - MedImmune released in the run up to the Immuno-Oncology Conference, taking place on the 26 - 27 September 2018 in London.
Researchers have discovered how the immune system might protect a person from recurrent bacterial skin infections caused by Staphylococcus aureus...
AstraZeneca and MedImmune, have today announced that the US Food and Drug Administration has granted breakthrough therapy designation for Imfinzi for the treatment of patients with locally-advanced, unresectable non-small cell lung cancer...
In this Imaging In-Depth Focus: Norman Peterson, from MedImmune/AstraZeneca, looks at the practical application of in vivo optical imaging in biotherapeutic biodistribution analyses. Plus, experts from MRC Technology discuss high-content imaging in drug discovery, and Molecular Devices feature in our Q&A...
29 March 2016 | By Victoria White
Inovio has updated its clinical strategy to take its INO-3112 HPV immunotherapy into human studies in combination with selected molecules from MedImmune...
11 December 2015 | By Victoria White
The companies have joined WCPR to develop new technologies for biologics production and to identify new targets for disease research in the ground-breaking area of the Secretome...
25 September 2015 | By Victoria White
TLR agonists are promising agents that activate innate immune cells and enhance the visibility of cancer tumours...
21 September 2015 | By Victoria White
DARPA is to provide the additional $24 million after Inovio successfully completed certain preclinical and clinical development milestones relating to the Ebola treatment programme...
14 September 2015 | By Victoria White
The new laboratory, opened in Cambridge, will focus on the discovery and development of novel biologic cancer treatments and diagnostics...
6 August 2015 | By Victoria White
MedImmune has entered into an exclusive clinical trial collaboration with Mirati Therapeutics to evaluate durvalumab in combination with mocetinostat...
24 April 2015 | By Victoria White
AstraZeneca and Celgene collaborate for the development and commercialisation of MEDI4736 across a range of blood cancers, including non-Hodgkin’s lymphoma...
8 April 2015 | By Victoria White
Inovio has been selected to receive a grant from DARPA to lead a collaborative team to develop multiple treatment and prevention approaches against Ebola...
13 January 2015 | By Astrazeneca
AstraZeneca announced that MedImmune, its global biologics research and development arm, has entered into a licensing agreement with Omnis Pharmaceuticals (Omnis), a privately-held biotechnology company focused on the development of oncolytic viruses...